scholarly journals Effect of RenaGel(R), a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients

1998 ◽  
Vol 13 (9) ◽  
pp. 2303-2310 ◽  
Author(s):  
D Goldberg
Keyword(s):  
Parathyroid Hormone ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Phosphate Binder ◽  
Serum Phosphorus ◽  
Intact Parathyroid Hormone ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Lack of Comparability of Intact Parathyroid Hormone Measurements among Commercial Assays for End-Stage Renal Disease Patients: Implication for Treatment Decisions

2006 ◽  
Vol 52 (9) ◽  
pp. 1771-1776 ◽  
Author(s):  
Tom Cantor ◽  
Zan Yang ◽  
Nicolae Caraiani ◽  
Ekambaram Ilamathi
Keyword(s):  
Parathyroid Hormone ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Method Comparison ◽  
Intact Parathyroid Hormone ◽  
Intact Pth ◽  
Edta Plasma ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

Abstract Background: Variability among assays used to measure intact parathyroid hormone (iPTH) is of particular concern because of the routine use of iPTH assay results to guide management of osteodystrophy and calcium metabolism in patients with end-stage renal disease (ESRD). The aim of this study was to determine the extent to which results from commercially available iPTH assays diverge from results obtained with the Nichols Allegro® Intact PTH immunoradiometric assay (IRMA), which was used as evidence in the development of the National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative Clinical Practice Guidelines. Methods: We divided EDTA plasma from 46 dialysis patients with ESRD and measured iPTH values with the following commercially available iPTH assays: Nichols’ Allegro iPTH IRMA, Nichols Advantage® iPTH immunochemiluminescent assay (ICMA), Scantibodies’ Total Intact PTH™ IRMA, DiaSorin’s N-tact® iPTH IRMA, DPC’s Coat-A-Count® iPTH IRMA, Roche’s Elecsys® iPTH ICMA, and DSL’s Active® iPTH IRMA. Results: Method comparison showed considerable interassay differences in the measurement of iPTH in ESRD patients. IPTH values assessed by other methods ranged, on average, from 60% to 152% of the Nichols Allegro IRMA values. Of the 6 iPTH assays tested, only the Scantibodies Total Intact PT IRMA (P = 0.7554) and the Roche Elecsys iPTH ICMA (P = 0.1327) resulted in iPTH values not statistically different from those obtained with the Nichols Allegro iPTH IRMA. Conclusions: Noncomparability among iPTH assays remains a distinct problem for the management of ESRD patients. These results should be taken into consideration when determining the course of medical treatment based on measured iPTH concentrations

scholarly journals The prevalence and incidence of vertebral fractures in end-stage renal disease and the role of parathyroid hormone

2019 ◽  
Vol 31 (3) ◽  
pp. 515-524
Author(s):  
T. T. Jansz ◽  
N. A. Goto ◽  
A. J. van Ballegooijen ◽  
H. C. Willems ◽  
M. C. Verhaar ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Renal Disease ◽  
Vertebral Fractures ◽  
End Stage Renal Disease ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Serum phosphorus predicts incident chronic kidney disease and end-stage renal disease

2011 ◽  
Vol 26 (9) ◽  
pp. 2885-2890 ◽  
Author(s):  
C. M. O'Seaghdha ◽  
S.-J. Hwang ◽  
P. Muntner ◽  
M. L. Melamed ◽  
C. S. Fox
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Serum Phosphorus ◽  
Incident Chronic Kidney Disease ◽  
Stage Renal Disease ◽  
End Stage
Sign in / Sign up

Export Citation Format

Share Document